At 7:25 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell.For active traders, premarket trading offers a head start in spotting potential breakouts, reversals, or sharp price swings. These early moves often indicate where momentum may carry into the regular session, making premarket analysis a key part of the trading day.In the Green - Premarket GainersThe following stocks are trading hig ...

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

Round led by new investor Life Sciences at Goldman Sachs Alternatives with participation by new investor the Retinal Degeneration Fund, and supported by existing investorsFunds will advance laru-zova toward commercialization for treatment of X-linked retinitis pigmentosa and accelerate development of additional pipeline candidates LONDON and CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnolog ...

Core Insights - The stock market showed mixed performance with Dow Jones, S&P 500, and Nasdaq futures slightly declining early Thursday, following a generally lower trend on Wednesday [3] - Eli Lilly confirmed its plan to acquire Ventyx Biosciences for $1.2 billion, which is a significant move in the biotech sector [6] - Quantum computing stocks have started strong in 2026, indicating potential growth in this emerging industry [5][8] Company Highlights - Eli Lilly's acquisition of Ventyx Biosciences is a strategic move to enhance its portfolio, particularly in the biotech space [6] - The stock of Eli Lilly is highlighted as a key focus for investors, with two potential entry points identified amid the rumored buyout rally [6] - Other notable companies in focus include Google and Nvidia, which are also nearing buy points as part of a broader market analysis [6] Industry Trends - The biotech sector is showing resilience with companies like Eli Lilly and Ionis Pharmaceuticals performing well [3] - The aerospace industry is represented by companies like Woodward, which have been added to top stock lists, indicating growth potential [3][4] - The quantum computing sector is gaining traction, suggesting a promising outlook for investors in this field [5][8]

Accessible version US Biopharmaceuticals 2026 Year Ahead: What to expect from our coverage universe in 2026 Price Objective Change Biopharma favorable despite lingering uncertainties Despite its challenges, Biopharma ended 2025 on a high note (NBI +32%, DRG +21% vs. SPX +17%)—with, in our view, reasons for optimism heading into 2026. Admittedly, the macro concerns weighing on 1H25 sentiment (inflation, tariffs) remain overhangs. That said, 1) sector-specific worries, mostly around drug pricing, eased; 2) lo ...

Core Insights - The healthcare sector underperformed in 2025, but there are still solid investment opportunities in smaller biotech companies [1] - Axsome Therapeutics and Exelixis are highlighted as promising investment options for 2026 and beyond [2] Axsome Therapeutics - Axsome Therapeutics has made steady clinical and regulatory progress, with approved products including Auvelity for depression, Symbravo for migraines, and Sunosi for narcolepsy [3] - The company is close to earning approval for Auvelity in treating Alzheimer's disease agitation, which could address a significant unmet need, as approximately 5 million patients in the U.S. experience this condition [4] - Axsome's revenue for the first nine months of 2025 reached $442.5 million, marking a 65.8% increase year-over-year [7] - The company has several late-stage pipeline candidates, including AXS-12 for narcolepsy and AXS-14 for fibromyalgia, which could further boost revenue [6][8] Exelixis - Exelixis specializes in oncology, primarily generating revenue from Cabometyx, which is approved for various cancers, including liver and kidney cancer [9] - The company reported $1.7 billion in revenue for the first nine months of 2025, a 7.5% increase compared to the same period in 2024 [10] - Exelixis has successfully defended its patent rights, delaying generic competition until the next decade [10] - The company is developing new products, including Zanzalintinib for metastatic colorectal cancer, which has shown strong phase 3 results and could significantly impact sales [12][14] - Exelixis is expected to submit regulatory applications soon, which will help diversify its portfolio beyond Cabometyx [13]

Clene Inc. (NASDAQ: CLNN) is a biotechnology company focused on developing innovative treatments for neurodegenerative diseases. The company is known for its pioneering work in nanotherapeutics, which involves using nanotechnology to create new medical treatments. Clene's competitors include other biotech firms working on similar therapies, such as Biogen and Novartis.On January 7, 2026, Ugwumba Chidozie, a significant shareholder of CLNN, sold 3,938 shares at $6.29 each. This transaction is part of a serie ...

Core Viewpoint - Bright Minds Biosciences Inc. has announced a public offering of 1,945,000 common shares at a price of $90.00 per share, aiming for gross proceeds of $175,050,000 to fund clinical trials and research initiatives [1][3]. Group 1: Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 291,750 common shares at the public offering price [1]. - The closing of the offering is expected on January 9, 2026, pending customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to fund future clinical trials for drug candidates targeting absence seizures, DEE, and Prader-Willi Syndrome, as well as initiating phase 1 clinical trials for BMB-105 and additional R&D for earlier phase programs [3]. Group 3: Company Background - Bright Minds is a biotechnology company focused on developing innovative treatments for neurological and psychiatric disorders, with a pipeline that includes novel compounds targeting key brain receptors [7]. - The company has developed a unique platform of highly selective serotonergic agonists, contributing to a rich portfolio of new chemical entity programs within neurology and psychiatry [8].

Core Viewpoint - Bright Minds Biosciences Inc. has announced a public offering of 1,945,000 common shares at a price of $90.00 per share, aiming for gross proceeds of $175,050,000 to fund clinical trials and research initiatives [1][3]. Group 1: Offering Details - The public offering consists of 1,945,000 common shares priced at $90.00 each, with expected gross proceeds of $175,050,000 [1]. - The underwriters have a 30-day option to purchase an additional 291,750 common shares at the public offering price [1]. - The closing of the offering is anticipated on January 9, 2026, pending customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to fund future clinical trials for drug candidates targeting absence seizures, developmental and epileptic encephalopathies (DEE), and Prader-Willi Syndrome [3]. - The funds will also support the initiation of phase 1 clinical trials for BMB-105 and additional research and development for earlier phase programs, along with general corporate and working capital purposes [3]. Group 3: Regulatory and Compliance - The company has filed a shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission (SEC), which became effective on September 2, 2025 [4]. - The offering is being conducted solely through a prospectus and a prospectus supplement that are part of the registration statement [4]. Group 4: Company Overview - Bright Minds is a biotechnology company focused on developing innovative treatments for neurological and psychiatric disorders, with a pipeline that includes novel compounds targeting key brain receptors [7]. - The company aims to deliver breakthrough therapies for conditions with high unmet medical needs, including epilepsy and depression [7][8].

Core Viewpoint - Monte Rosa Therapeutics (GLUE) is experiencing a positive shift in market perception, with upgrades from Jefferies and Zacks Investment Research indicating strong future performance potential [1][2][5] Group 1: Stock Performance - Jefferies upgraded GLUE's stock grade to "Buy" with a current price of $22.95, later adjusted to $23.29, reflecting a significant increase of 45.44% with a price change of $7.28 [1][3][5] - The stock has fluctuated between a low of $21.11 and a high of $25.15 today, with the latter being its highest price in the past year [3] - The lowest price for the year was $3.50, indicating notable volatility in the stock [3] Group 2: Market Metrics - Monte Rosa Therapeutics has a market capitalization of approximately $1.52 billion, showcasing its size and market presence [4] - The trading volume stands at 22.72 million shares, reflecting active investor interest and confidence in the company's future prospects [4] Group 3: Analyst Ratings - Jefferies raised the price target for GLUE from $22 to $31, indicating strong confidence in the company's future performance [2][5] - Zacks Investment Research upgraded GLUE to a Zacks Rank 1 (Strong Buy), emphasizing a positive earnings trend that supports the stock's upward movement [2][5]